首页> 外文期刊>Кардиология >Effect of twelve-month combined therapy with perindopril and indapamide on the level of blood pressure and left ventricular hypertrophy in patients with hypertensive disease
【24h】

Effect of twelve-month combined therapy with perindopril and indapamide on the level of blood pressure and left ventricular hypertrophy in patients with hypertensive disease

机译:培哚普利联合吲达帕胺十二个月联合治疗对高血压患者血压和左心室肥厚的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Left ventricular hypertrophy (LVH) in patients with hypertensive disease is associated with unfavorable prognosis. Long term and effective antihypertensive therapy is capable to cause reverse development of LVH. We included in this study 72 patients (27 men, 45 women, age from 34 to 72 years) with untreated 1st and 2nd degree arterial hypertension (systolic blood pressure 140-179 mm Hg and/or diastolic blood pressure 99-109 mm Hg) and echocardiographical signs of LVH (left ventricular myocardial mass index >120 g/m2 in men and >100 g/m2 in women). After that the patients were randomized into 2 groups: the study group (39 patients, mean age 53.0+/-11.6 years) received combination of perindopril and indapamide in initial dose of 2 mg/0.625 mg, and comparison group (33 patients, mean age 54.4+/-8.2 years) received monotherapy with enalapril (10 mg). Once daily dosing of the preparation provided high level of compliance of patients with treatment. During 12-month therapy with combination of perindopril andindapamide target blood pressure (<140/90) was achieved in 74.4% of patients, during monotherapy with enalapril--in 27.3% of patients. Significant decrease of left ventricular myocardial mass index (LVMMI) with combination therapy was observed by 6th month of treatment (from 260 to 234 g), with monotherapy within same period of time--from 267 to 260 g. As a result of 12 months therapy of patients with I-II degree of hypertension with perindopril and indapamide LVMMI decreased by 17.5% while monotherapy with enalapril was associated with 5.6% decrease of LVMMI. Lowering of LVMMI occurred mainly at the account of decrease of left ventricular wall thickness.
机译:高血压病患者的左心室肥大(LVH)与不良预后相关。长期有效的降压治疗能够引起LVH逆向发展。我们在这项研究中纳入了72例未治疗的1级和2级动脉高血压(收缩压140-179 mm Hg和/或舒张压99-109 mm Hg)(27名男性,45名女性,年龄从34至72岁)和LVH的超声心动图征象(男性左心室心肌质量指数> 120 g / m2,女性> 100 g / m2)。之后,将患者随机分为两组:研究组(39例,平均年龄为53.0 +/- 11.6岁)接受培哚普利和吲达帕胺的初始剂量分别为2 mg / 0.625 mg的组合,对照组为33例,平均(年龄54.4 +/- 8.2岁)接受依那普利(10毫克)单药治疗。每天一次给药制剂为患者提供了高水平的治疗依从性。在使用培哚普利和吲达帕胺联合治疗的12个月期间,达到目标血压(<140/90)的患者达到74.4%,在使用依那普利的单药治疗期间达到27.3%的患者。在治疗的第6个月(从260到234 g)观察到联合治疗的左心室心肌质量指数(LVMMI)显着降低,在同一时间段内从267到260 g进行了单一治疗。培哚普利和吲达帕胺LVMMI治疗I-II级高血压患者12个月,结果降低了17.5%,而依那普利单药治疗则使LVMMI降低了5.6%。 LVMMI降低主要是由于左心室壁厚度的降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号